Dossier assessment
Mepolizumab - Benefit assessment according to §35a Social Code Book V
Report documents
-
Dossier assessment
Mepolizumab - Benefit assessment according to §35a Social Code Book V
Press releases
Mepolizumab in severe asthma: added benefit not proven
Appropriate comparator therapy not implemented, indirect comparison unsuitable
Additional information
Federal Joint Committee (G-BA)
2016-07-21 A G-BA decision was published.
Project details
- Project no.
- A16-03
- Commission
- Commission awarded on 29.01.2016 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Mepolizumab (asthma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Mepolizumab (COPD) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Mepolizumab (eosinophilic granulomatosis with polyangiitis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Mepolizumab (hypereosinophilic syndrome) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Mepolizumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed